BofA initiated coverage of Taysha Gene Therapies (TSHA) with a Buy rating and $8 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Buy Rating for Taysha Gene Therapies: Favorable Study Design and High Responder Rate
- Craig-Hallum bullish on Neurogene, initiates with a Buy
- Promising Potential of Taysha Gene Therapies: Buy Rating Affirmed by Maury Raycroft
- Taysha Gene Therapies price target raised to $13 from $7 at Cantor Fitzgerald
- Positive Outlook for Taysha Gene Therapies’ TSHA-102: Promising Clinical Data and Commercial Viability Justify Buy Rating